Filed by Flex Pharma, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule
under the Securities Exchange Act of 1934
Subject Company: Salarius Pharmaceuticals, LLC
SEC File No.:
Flex Pharma, Inc. intends to issue the following press release.
Flex Pharma Announces Rights Dividend
BOSTON(BUSINESS WIRE)July 18, 2019 Flex Pharma, Inc. (Nasdaq: FLKS) announced that its Board of Directors today declared a special dividend
on the Companys common stock of one right per share of outstanding common stock. The rights will be paid on July 19, 2019 to shareholders of record as of close of business on July 18, 2019.
Flex Pharma has not listed, and does not intend to list, the rights for trading on any exchange. The terms of the rights are described in Flex Pharmas
definitive proxy statement / prospectus / information statement dated April 29, 2019 (the Proxy Statement), as supplemented by the Supplement dated June 27, 2019 (the Supplement), both of which Flex Pharma filed
with the Securities and Exchange Commission.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, LLC is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that
need them the most. The companys lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug Designation and Rare Pediatric Disease Designation by the U.S. Food and Drug
Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other
LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet need, with an ongoing clinical study in advanced solid tumors including, but not limited to, prostate, breast and ovarian cancers. Salarius
receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7M Product Development Award from the Cancer Prevention and Research Institute of Texas
(CPRIT). For more information, please visit salariuspharma.com.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that was founded in 2014 by National Academy of Science members Rod MacKinnon, M.D. (2003 Nobel Laureate) and
Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology.